gms | German Medical Science

61. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie

16. - 17.04.2015, Köln

Identification of novel long non-coding RNAs in clear cell renal cell carcinoma

Meeting Abstract

  • J. Ellinger - Universitätsklinikum Bonn, Urologie, Bonn, Germany
  • J. Blandeau - Universitätsklinikum Bonn, Urologie, Bonn, Germany
  • M. Deng - Universitätsklinikum Bonn, Pathologie, Bonn, Germany
  • I. Syring - Universitätsklinikum Bonn, Urologie, Bonn, Germany
  • S. Schrödter - Universitätsklinikum Bonn, Urologie, Bonn, Germany
  • D. Schmidt - Universitätsklinikum Bonn, Urologie, Bonn, Germany
  • S. Perner - Universitätsklinikum Bonn, Urologie, Bonn, Germany
  • S. Müller - Universitätsklinikum Bonn, Urologie, Bonn, Germany

Nordrhein-Westfälische Gesellschaft für Urologie. 61. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie. Köln, 16.-17.04.2015. Düsseldorf: German Medical Science GMS Publishing House; 2015. DocP1.5

doi: 10.3205/15nrwgu052, urn:nbn:de:0183-15nrwgu0528

Veröffentlicht: 13. März 2015

© 2015 Ellinger et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Introduction: Long non-coding RNAs (lncRNA) play an important role in carcinogenesis; knowledge on lncRNA expression in renal cell carcinoma is rudimental. As a basis for biomarker development, we aimed to explore the lncRNA expression profile in clear cell renal cell carcinoma (ccRCC) tissue.

Methods: Microarray experiments were performed to determine the expression of 32,183 lncRNA transcripts belonging to 17,512 lncRNAs in 15 corresponding normal and malignant renal tissues. Validation was performed using quantitative real-time PCR in 55 ccRCC and 52 normal renal specimen. Computational analysis was performed to determine lncRNA-microRNA (MiRTarget2) and lncRNA-protein (catRAPID omics) interactions.

Results: We identified 1308 dysregulated transcripts (expression change >2-fold; upregulated: 568, downregulated 740) in ccRCC tissue. Among these, aberrant expression was validated using PCR: lnc-BMP2-2 (mean expression change: 37-fold), lnc-CPN2-1 (13-fold), lnc-FZD1-2 (9-fold), lnc-ITPR2-3 (15-fold), lnc-SLC30A4-1 (15-fold) and lnc-SPAM1-6 (10-fold) were highly overexpressed in ccRCC, whereas lnc-ACACA-1 (135-fold), lnc-FOXG1-2 (19-fold), lnc-LCP2-2 (2-fold), lnc-RP3-368B9 (19-fold) and lnc-TTC34-3 (314-fold) were downregulated. There was no correlation between lncRNA expression with clinical-pathological parameters. Computational analyses revealed that these lncRNAs are involved in RNA-protein networks related to splicing, binding, transport, localization and processing of RNA; loss of lnc-FOXG1-2 may contribute to the increase of miR-519c-3p, and thereby induce angiogenesis. siRNA-mediated knockdown of lnc-BMP2-2 and lnc-CPN2-1 did not influence cell proliferation.

Conclusion: We identified many novel lncRNA transcripts dysregulated in ccRCC which may be useful for novel diagnostic biomarkers.